Additional illustrative linker intermediates (also referred as folate spacers) are described herein: EC 014 EC0014: 1H NMR (D 2 0, 500 MHz) 5(ppm) 8.73(s, IH, FA H-7), 7.56 (d, 2H, FA H-12&H16), 6.73(d, 2H, FA H-13&H15), 4.45(m, 2H), 4.1(m, 2H), 3.61(d, 2H), 2.82(m, 3H), 2.74(dd, IH), 2.37(m, 2H), 2.18(m, IH), 2.09(m, 3H), 1.74(m, IH) EXAMPLE Pte-y-D-Glu- -Dap-Asp-Cys EC0020: MS (ESI, [M+H] + ) 746
I'm gonna quote Alex Telford who wrote this really amazing, long blog post explaining how the clinical trial process works, why drug development has gotten so expensive, and all that
BoggianoMMChandlerPCOswaldKDRodgersRJBlundellJEIshiiY.et al
Common types include semaglutide, liraglutide, tirzepatide, dulaglutide and exenatide
a reduction to $675/month takes effect January 1, 2027) and Zepbound at ~$1,086/month (tirzepatide, per Eli Lillys published list price), both before insurance or coupons